Synthesis, in vitro a glucosidase inhibition, antioxidant, in vivo antidiabetic and molecular docking studies of pyrrolidine 2,5 dione and thiazolidine 2,4 dione derivatives.
a Glucosidase is considered as a therapeutic target for the treatment of type 2 diabetes mellitus (DM2) In current study, we synthesized pyrrolidine 2,5 dione (succinimide) and thiazolidine 2,4 dione derivatives and evaluated for their ability to inhibit a Glucosidase. Pyrrolidine 2,5 dione derivatives (11a o) showed moderate to poor a glucosidase inhibition. Compound 11o with the IC50 value of 28.3 0.28 uM emerged as a good inhibitor of a glucosidase. Thiazolidine 2,4 dione and dihydropyrimidine (TZD DHPM) hybrids (22a c) showed excellent inhibitory activities. The most active compound 22a displayed IC50 value of 0.98 0.008 uM. Other two compounds of this series also showed activity in low micromolar range. The in vivo antidiabetic study of three compounds 11n, 11o and 22a were also determined using alloxan induced diabetes mice model. Compounds 11o and 22a showed significant hypoglycemic effect compared to the reference drug. In vivo acute toxicity study showed the safety of these selected compounds. In silico docking studies were carried out to rationalize the in vitro results. The binding modes and bioassay results of TZD DHPM hybrids showed that interactions with important residues appeared significant for high potency.
Bioorganic chemistry